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Abstract 1	  
Liver disease is a leading cause of death in the Western World. However, our insight 2	  
into the underlying disease mechanisms and development of novel therapeutic 3	  
agents has been hindered by limited availability of primary tissue, intra-species 4	  
variability associated with the use of animal models and reduced long-term viability of 5	  
isolated and diseased liver cells. The emergence of hIPSCs (human Induced 6	  
Pluripotent Stem Cells) and differentiation protocols to generate hepatocyte-like cells 7	  
has opened the possibility of addressing these issues. Here we discuss the recent 8	  
progress and potential in the production of various cell types constituting the liver and 9	  
their applications to model liver diseases and test drug toxicity in vitro.  10	  
4	  	  
Liver disease constitutes a leading cause of death worldwide (1). However, 1	  
depending on the etiology, treatment options can be limited and liver transplantation 2	  
remains the only available therapy for end stage liver failure (2). Understanding the 3	  
disease pathogenesis is crucial for developing new therapeutic agents and 4	  
diagnostic modalities. Although existing models for the study of hepatic disorders 5	  
have proven very useful, they also exhibit significant limitations. In vivo models are 6	  
constrained by intra-species variability (3), while the use of primary tissue is limited 7	  
by poor availability and technical challenges in culturing primary cells (4). 8	  
Furthermore, established cell lines are restricted by their malignant background and 9	  
the requirement for non-physiological manipulations, such as protein overexpression, 10	  
to replicate the disease phenotype. 11	  
Human Induced Pluripotent Stem Cells (hIPSCs) derived from reprogrammed 12	  
somatic cells (5) demonstrate great potential for overcoming such challenges. Their 13	  
capacity for self-renewal and differentiation into almost any cell type provides a 14	  
unique system for generating large quantities of autologous, disease-specific liver 15	  
cells in vitro. Cells generated through this system constitute an optimal platform for 16	  
modeling hepatic disorders, provided that they closely resemble their native 17	  
counterparts, recapitulate key aspects of the disease in question and demonstrate 18	  
measurable responses to therapeutic agents. 19	  
Here, we review how these requirements are addressed by existing culture systems 20	  
for the generation of hIPSC-derived hepatocytes, describe their applications for 21	  
modeling hepatic disorders and discuss future directions for the use of hIPSCs in the 22	  
study of liver disease. 23	  
 24	  
Current approaches for the generation of liver cells from hIPSCs 25	  
Given the potential of hIPSCs for modeling hepatic disease, the derivation of different 26	  
liver cell populations has been the subject of intensive research. Most of these efforts 27	  
have concentrated on the generation of hepatocytes, which occupy the largest 28	  
5	  	  
proportion of the organ volume and are responsible for the majority of its metabolic 1	  
functions including detoxification, glucose metabolism, synthesis of plasma proteins 2	  
and bile production (6). However, the metabolic activity of hepatocytes is supported 3	  
by multiple other cell types collectively known as non-parenchymal liver cells. This 4	  
heterogeneous population includes sinusoidal endothelial cells, hepatic stellate cells, 5	  
Kupffer cells and cholangiocytes (6). With the exception of cholangiocytes, 6	  
differentiation of hIPSCs to non-parenchymal cell types of the liver has not yet been 7	  
reported. In this section, we concentrate on current platforms for the generation of 8	  
hIPSC-derived hepatocytes and cholangiocytes, their advantages and limitations. 9	  
Hepatocytes 10	  
Primary hepatocytes remain the gold standard for in vitro modeling of liver diseases. 11	  
However, hIPSC-derived hepatocyte-like-cells (HLCs) could present an excellent 12	  
alternative for addressing availability issues, provided they recapitulate key features 13	  
of their native counterparts. Indeed, a minimum set of criteria need to be met prior to 14	  
characterizing hIPSC-derived cells as ‘hepatocyte-like’. These include expression of 15	  
hepatic markers at gene and protein level, demonstration of specific ultrastructural 16	  
characteristics, production of albumin, urea and fibrinogen, induction of P450 17	  
enzymatic activity following treatment with specific inducers and the use of selected 18	  
substrates to confirm phase 1 and 2 metabolic enzyme activity (7-10). 19	  
To fulfill these criteria, multiple groups have developed protocols of directed 20	  
differentiation towards HLCs (11-16), aimed at recapitulating key stages of natural 21	  
liver development including definitive endoderm, foregut, hepatic endoderm, 22	  
bipotential hepatoblasts and hepatocyte like cells (17) (Figure 1). All these 23	  
approaches converge on the modulation of pathways known to have a pivotal role in 24	  
hepatic embryogenesis, such as FGF, BMP4, Wnt, Activin and HGF signaling (17). 25	  
The resulting cells bear significant similarities to primary hepatocytes in terms of 26	  
transcriptional profile and functional properties, such as albumin and apolipoprotein 27	  
B100 (ApoB100) secretion, functional bile transport, LDL uptake, urea synthesis, 28	  
6	  	  
cytochrome P450 activity (Cyp3A4) and glycogen storage (16,18). However, HLCs 1	  
resemble more closely fetal rather than adult hepatocytes, with ongoing expression 2	  
of fetal markers (AFP) and embryonic P450 activity (Cyp3A7) (Table 1).  3	  
The fetal identity of HLCs has given rise to a plethora of studies focusing on 4	  
increasing their functionality. Among these approaches two main strategies emerge: 5	  
The first concentrates on increasing differentiation efficiency, promoting maturation 6	  
or enhancing P450 activity and drug metabolism. The use of small molecule 7	  
compounds (19-20), sequential overexpression of transcription factors controlling 8	  
various stages of hepatic development (17), direct reprogramming of fibroblasts to 9	  
induced Hepatic Stem Cells through forced expression of hepatic transcription 10	  
factors (21-22) and direct reprogramming of fibroblasts to endoderm progenitor cells 11	  
by combining overexpression of OCT4, SOX2 and Klf4 with small molecule treatment 12	  
(23) have all been reported to contribute towards achieving this goal. Therefore, it is 13	  
possible that such methodologies will increasingly complement growth factors driven 14	  
differentiation of hIPSCs in the future. 15	  
The second strategy focuses on accurately simulating the liver microenvironment 16	  
through 3D culture of HLCs (24), co-culture with endothelial or non-parenchymal 17	  
cells (25), the use of artificial scaffolds (26) or a combination of these techniques 18	  
(27). These approaches have also been reported to increase functionality, optimize 19	  
the transcriptional profile of HLCs and even allow the generation of functional liver 20	  
organoids with the capacity to engraft in the vasculature of immunodeficient mice 21	  
(27).  22	  
Considered collectively, these advances have contributed towards bridging the gap 23	  
between primary hepatocytes and HLCs (Figure 1). However, many challenges 24	  
remain prior to fully achieving this goal, such as the limited capacity of HLCs to 25	  
repopulate the liver of animal models of hepatic failure. Furthermore, considering the 26	  
notable differences between primary hepatocytes cultured in vitro and their native 27	  
counterparts, it is possible that there is a limit to how closely in vitro HLCs can 28	  
7	  	  
reproduce the phenotype and function in vivo hepatocytes. Indeed, culture systems 1	  
maintaining the full functional repertoire of primary hepatocytes are yet to be 2	  
developed and until then, generation of fully mature hepatocytes in vitro might remain 3	  
elusive. 4	  
Cholangiocytes 5	  
Cholangiocytes constitute the main cell type affected by diseases of the biliary 6	  
system, or cholangiopathies. Therefore, differentiation of hIPSCs to cholangiocyte-7	  
like cells could provide a novel platform for the study of biliary disorders and the 8	  
development of new therapeutic agents. The generation of hIPSC-derived 9	  
cholangiocyte-like cells (CLCs) and organoids has been reported by various groups 10	  
(28-32). The common denominator in these approaches is the suspension of 11	  
hepatoblast- or cholangiocyte progenitor-like cells in Matrigel supplemented with 12	  
EGF, Wnt or HGF. The cells re-organize in 3D polarized structures expressing biliary 13	  
markers and lacking expression of hepatic markers. The resulting organoids exhibit 14	  
secretory functionality (28,29,32), alkaline phospatase (30) and gamma-glutamyl 15	  
transpeptidase activity (31), as well as responses to hormonal stimuli including 16	  
somatostatin (32). Despite these advances, the relevance of these approaches to 17	  
natural development remains vague, which limits their applications for developmental 18	  
studies and drug screening. Therefore, further optimization of the current culture 19	  
systems remains a prerequisite for effectively modeling cholangiopathies using 20	  
hIPSCs.  21	  
 22	  
Disease models to date 23	  
Since the first proof-of-principle that patient-specific HLCs can be used to model liver 24	  
diseases (33), the field has expanded rapidly to address a broad range of disorders. 25	  
Here we review the current hIPSCs-based models for liver disease and their 26	  
contribution to advancing our insight in the pathophysiology of hepatic disorders 27	  
(Table 2, Figure 2). 28	  
8	  	  
 1	  
Disease caused by accumulation of misfolded proteins 2	  
α1-Antitrypsin (A1AT) Deficiency: A1AT deficiency is an autosomal recessive 3	  
disorder caused by mutations in the A1AT-endcoding SERPINA1 gene (34). A1AT is 4	  
a protease inhibitor synthesized primarily by hepatocytes. SERPINA1 mutations lead 5	  
to low levels of serum and alveolar A1AT, which is associated with panlobular 6	  
emphysema from over-active proteases such as pulmonary neutrophil elastase. 7	  
Retention of misfolded A1AT polymers within the hepatic endoplasmic reticulum (ER) 8	  
results in hepatic dysfunction and liver disease (34). A1AT deficiency was the first 9	  
hepatic disorder to be modelled in vitro using hIPSCs, by differentiating patient-10	  
derived hIPSCs into A1AT polymer-retaining HLCs. The disease phenotype was 11	  
confirmed by ELISA and immunocytochemistry for the polymeric form of A1AT, as 12	  
well as ER-specific enzyme digests, which indicated entrapment of A1AT in the ER. 13	  
In a subsequent study, the same group reported rescue of the disease phenotype, 14	  
following correction of the SERPINA1 mutation using zinc finger nucleases, thereby 15	  
demonstrating a direct association between the phenotype observed and the 16	  
underlying genetic defect (35). These results illustrate the potential of hIPSCs for 17	  
genetic correction, which represents a powerful tool for dissecting the mechanisms of 18	  
inherited disorders and generating autologous healthy tissue for personalised cell-19	  
based therapy. 20	  
Familial Transthyretin Amyloidosis (FTA): FTA is a lethal autosomal dominant 21	  
disease, caused by mutations in the transthyretin-encoding TTR gene, leading to 22	  
secretion of monomeric misfolded TTR proteins by the liver and formation of 23	  
extracellular fibrils accumulating as amyloid in target organs, mainly the brain and 24	  
heart (36). Although the liver participates in the disease pathogenesis through the 25	  
production of pathological TTR, it does not sustain end organ damage (37). 26	  
Consequently, in vitro modeling of FTA has been limited by the requirement of 27	  
multiple cell types to capture the complexity of the disease. These include 28	  
9	  	  
hepatocytes for studying the mechanisms controlling TTR production and misfolding, 1	  
as well as several target cell populations for interrogating the effects of the TTR 2	  
mutation products.  3	  
The capacity of hIPSCs to differentiate towards almost any cell type renders them an 4	  
ideal platform to overcome this challenge. Indeed, recently Leung et al. reported the 5	  
generation of hepatocytes, cardiomyocytes and neurons from hIPSCs of patients 6	  
with FTA (37). Neurons and cardiomyocytes exposed to hepatocyte-secreted mutant 7	  
TTR, using conditioned media, exhibited oxidative stress and increased cell death. 8	  
More importantly, the use of small molecules stabilizing TTR exerted a protective 9	  
effect on the target cell populations (37). Considered collectively, these results 10	  
illustrate the potential of hIPSCs for modeling diseases affecting several organs 11	  
simultaneously. 12	  
 13	  
Liver diseases caused by disruption of enzymatic activity 14	  
Glycogen Storage Disease type 1a (GSD1a): GSD1a is a rare autosomal recessive 15	  
disorder caused by mutations in the G6PC-encoded glucose-6-phosphatase (G6PT) 16	  
(38). G6PT is essential for the regulation of glucose homeostasis through 17	  
gluconeogenesis and glycogenolysis (38). Consequently, G6PT deficiency manifests 18	  
with hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia. Lipid and 19	  
glycogen accumulation in liver and kidneys result in hepatorenomegaly, while growth 20	  
retardation is also reported. Importantly, glucagon stimulation in these patients 21	  
increases serum lactate but does not affect serum glucose levels (38).  22	  
GSD1a has been successfully modelled in vitro using patient-derived HLCs (33). 23	  
Indeed, GSD1a-HLCs exhibited increased glycogen and lipid accumulation 24	  
compared to wild-type controls, demonstrated through PAS and BODIPY staining 25	  
respectively. Furthermore, GSD1a-HLCs showed similar sensitivity to glucagon 26	  
stimulation compared to wild-type controls; however, lactate synthesis was 27	  
significantly increased in GSD1a-HLCs. Considered together these experiments 28	  
10	  	  
demonstrate the potential of hIPSCs for recapitulating key features of GSD1a in vitro, 1	  
including glycogen accumulation, hyperlipidemia and lactic acidosis. More 2	  
importantly, the capacity of HLCs for mimicking the native regulation of glucose and 3	  
lipid homeostasis, renders them a unique system for studying more complex 4	  
metabolic liver disorders associated with type 2 diabetes and metabolic syndrome, 5	  
such as liver steatosis and Non Alcoholic Steatohepatitis (NASH). 6	  
Wilson’s Disease (WD): WD is an autosomal recessive disorder caused by 7	  
mutations in the ATP7B gene, an ATPase expressed mainly in hepatocytes and 8	  
mediating hepatocellular excretion of copper in the bile and bloodstream. Hepatic 9	  
accumulation of copper results in liver damage leading to cirrhosis or in some cases 10	  
acute liver failure; while increased serum copper levels result in copper deposition 11	  
and toxicity, affecting multiple organs, mainly the brain, kidneys and cornea (39-40). 12	  
Current treatments with copper chelators are very effective in reducing copper serum 13	  
levels; however, liver transplantation remains the only treatment option for acute liver 14	  
failure and refractory disease (39). Concerning modeling of WD in vitro, 2 groups 15	  
have generated HLCs from WD patients, exhibiting abnormal cytoplasmic localization 16	  
of mutant ATP7B and defective copper transport (40-41). More importantly, Zhang et 17	  
al. reported rescue of the disease phenotype using the chaperone drug curcumin or 18	  
lentiviral overexpression of wild type ATP7B. These results provide proof-of-principle 19	  
for therapeutic approaches alternative to copper chelators in Wilson’s disease and 20	  
validate the potential of hIPSC-derived hepatocytes as an appropriate platform for 21	  
drug validation in the context of this disorder (40). 22	  
 23	  
Diseases caused by receptor dysfunction  24	  
Familial hypercholesterolemia (FH): FH represents the most common and severe 25	  
form of inherited hypercholesterolemia. The uptake and catabolism of LDL-C in the 26	  
liver is physiologically mediated by the low density lipoprotein receptor (LDLR) on the 27	  
membrane of hepatocytes. FH is caused by mutations in the LDLR inherited in an 28	  
11	  	  
autosomal codominant pattern, which result in poor hepatic uptake and high 1	  
circulating levels of plasma cholesterol levels (LDL-C) irrespective of diet, 2	  
medications or lifestyle, thereby leading to early onset of cardiovascular disease (42). 3	  
Furthermore, recent mouse studies suggest a role for LDLR in regulating plasma 4	  
levels of very low density lipoprotein (VLDL) and ApoB100 (42). However, human 5	  
data is extremely limited given the difficulties in obtaining primary tissue from FH 6	  
patients.  7	  
HLCs provide an excellent platform for addressing this challenge. Patient-derived 8	  
HLCs (33,43) exhibit reduced synthesis of LDLR and impaired receptor functionality 9	  
demonstrated by limited LDL-C uptake in FACS analysis and immunohistochemistry 10	  
assays (33). The capacity of this system to accurately reproduce the phenotype of 11	  
different LDLR mutations was demonstrated using a compound heterozygous patient 12	  
with a non-functional maternal allele and a paternal allele encoding a receptor with 13	  
physiological binding to LDL-C but defective internalization (43). The resulting HLCs 14	  
exhibited increased clustering of fluorescently-labelled LDL-C on the cell surface but 15	  
reduced uptake as a result of impaired endocytosis of LDL-C through the paternally-16	  
encoded mutant LDLR. These observations underline the potential of HLCs for 17	  
dissecting the impact of genetic variations on the disease phenotype. Furthermore, 18	  
the application of FH-HLCs for drug screening in FH was demonstrated by 19	  
reproducing the effects of lovastatin, a lipid-lowering agent, known to be ineffective 20	  
for patients with FH (44). Indeed, FH-HLCs exhibited minimal change in LDL-C 21	  
uptake compared to wild-type controls, which increased cholesterol uptake 22	  
appropriately (43). These results provide proof-of-principle for the suitability of FH-23	  
HLCs as a platform for testing the efficacy of lipid-lowering agents in the context of 24	  
FH. Finally, using this culture system, a role for LDLR in regulating ApoB100 levels in 25	  
human was identified. Indeed, FH-HLCs exhibited an 8-fold increase in secreted 26	  
ApoB100 compared to wild-type controls, in the absence of enhanced gene 27	  
expression, suggesting a mechanism involving post-translational degradation of 28	  
12	  	  
ApoB100 (43). These results demonstrate the potential of FH-HLCs as a model for 1	  
studying the molecular pathogenesis of FH. 2	  
 3	  
Infectious diseases of the liver 4	  
Hepatitis C Virus: Hepatocytes are susceptible to infection from multiple pathogens 5	  
including viruses   (Hepatitis A–E, CMV, EBV) and parasites (Plasmodium, 6	  
Schistosoma). However, the most common infective cause for liver transplantation is 7	  
viral infection with Hepatitis C (HCV) (2). Current treatment options for HCV offer 8	  
only a 50% viral clearance rate, while liver transplantation is complicated by disease 9	  
recurrence in the graft (2,45). Primary hepatocytes represent the gold standard for 10	  
studying the pathophysiology of hepatitis C viral infection; however, their limited 11	  
availability has led to the use of hepatoma lines such as Huh 7.5 (46-47). Although 12	  
these systems have proven useful for studying the disease, they are limited by 13	  
inherent differences from primary hepatocytes associated with their cancerous 14	  
nature, reduced infection efficiency and defects in interferon production. More 15	  
importantly, cell lines can only be infected by specific HCV genotypes and are 16	  
resistant to infection with human sera (47). HLCs provide an alternative platform for 17	  
the study of HCV that addresses some of these challenges. In particular, they 18	  
express the necessary receptors for the entry of HCV in the cells (47-49), support the 19	  
full life cycle of the virus (50) and reproduce key inflammatory responses to infection, 20	  
including TNFα and interleukin 28 secretion (47,50). In contrast to hepatoma lines, 21	  
HLCs can be infected using infected patient sera (47,49). Interestingly, using HLCs, 22	  
Wu et al. have identified key factors regulating permissiveness to viral infection 23	  
including the upregulation of micro-RNA 122 and suppression of antiviral genes such 24	  
as interferon-induced transmembrane protein-1 (47). Most importantly, the same 25	  
group generated genetically modified hepatocytes resistant to HCV infection, thereby 26	  
addressing a major challenge for liver transplantation and autologous cell therapy in 27	  
HCV patients; preventing recurrence of the disease in the transplanted tissue (2,47).  28	  
13	  	  
Considered collectively, these studies demonstrate the potential of hIPSCs for 1	  
modeling host-pathogen interactions in infectious hepatic disorders and constitute 2	  
the first example of HLCs used in the study of a non-genetic liver disease. 3	  
Importantly, a similar approach could be applied for the study of other common liver 4	  
pathogens, including HBV (51) or parasitic infections (52). 5	  
 6	  
The potential of hIPSCs for modeling complex liver disease 7	  
With the exception of HCV, all liver diseases modeled to date using hIPSCs 8	  
constitute rare monogenic metabolic disorders that collectively account for less than 9	  
10% of the total number of liver transplantations performed (2) (Table 2). Therefore, 10	  
a major challenge for regenerative medicine in hepatology is evolving from proof-of-11	  
principle models to modeling more complex disorders that constitute leading causes 12	  
for chronic liver disease and transplantation.  13	  
Modeling cirrhosis: Hepatic failure secondary to cirrhosis constitutes the endpoint 14	  
in the natural history of the majority of chronic liver disorders and one of the most 15	  
common causes of death in the Western world (2). It is caused by disruption of the 16	  
liver architecture due to excessive deposition of connective tissue by hepatic stellate 17	  
cells (53). However multiple other cell types contribute to the disease through 18	  
activating stellate cells or triggering inflammatory responses. These include 19	  
hepatocytes, Kupffer cells and sinusoidal endothelial cells (53). One of the major 20	  
difficulties in modeling cirrhosis in vitro is accurately reproducing these intricate 21	  
cellular interactions controlling the disease pathogenesis. To overcome this 22	  
challenge various approaches have been used. In vivo models based on 23	  
administration of toxic compounds, Schistosoma infection or bile duct ligation to 24	  
induce cirrhosis have proven useful; however they are not specific to the underlying 25	  
liver disease and they are limited by intra-species variability (54). In vitro models 26	  
based on 3D platforms enabling co-culture of primary hepatocytes and stellate cells 27	  
(53) address some of these issues; however, they are also restricted by poor access 28	  
14	  	  
to primary tissue. The use of hIPSCs-based platforms simulating the liver 1	  
microenvironment could contribute towards overcoming these limitations. Indeed, 2	  
introduction of stellate and Kupffer cells in existing organoid culture systems 3	  
combining HLCs, endothelial and stromal cell populations (25,27) could provide an 4	  
excellent model for studying the cellular interactions controlling the pathogenesis of 5	  
cirrhosis. In the absence of protocols for the generation of hIPSC-derived stellate 6	  
cells, stellate cell lines could be used, while macrophages acting as Kupffer cells 7	  
could be derived from hIPSCs or isolated from peripheral blood.  8	  
Finally, the most challenging aspect might not be to source all the cells necessary to 9	  
mimic the liver environment but to reproduce chronic hepatocyte injury in vitro. 10	  
Indeed, cirrhosis/fibrosis secondary to certain etiologies, such as congestive cardiac 11	  
failure can prove challenging to model especially in a culture system with a short 12	  
half-life (10). Furthermore, the impact of the fetal phenotype of HLCs for such 13	  
platforms remains unclear. To conclude, multicellular organoid platforms based on 14	  
HLCs could provide one of the most accurate systems to date for reproducing the 15	  
complexity of cirrhotic tissue in vitro. However, several challenges remain to be 16	  
addressed, which will require major advances in 3D co-culture systems. 17	  
 18	  
Modeling biliary disease: Bile duct disorders constitute an important cause for 19	  
chronic liver disease and transplantation (2). However, treatment options are 20	  
extremely limited (2) and our understanding of the disease pathogenesis is restricted 21	  
by lack of appropriate disease models. Indeed, in vivo models fail to fully recapitulate 22	  
the disease phenotype, while primary cholangiocytes are extremely difficult to culture 23	  
in vitro (55). CLCs could contribute towards addressing this challenge. Culture 24	  
systems recapitulating key stages of native biliary differentiation and tubulogenesis 25	  
could increase our insight into the mechanisms of bile duct specification and provide 26	  
an ideal platform for modeling infantile cholangiopathies caused by defects in biliary 27	  
tree development (56). Furthermore, patient-derived CLCs represent an excellent 28	  
15	  	  
system for interrogating the impact of genetic modifiers in the pathogenesis of 1	  
complex biliary disorders, such as Primary Biliary Cirrhosis (PBC). Recent genome-2	  
wide association studies have identified multiple loci associated with PBC (57), but 3	  
their expression and function in cholangiocytes remains largely unknown. CLCs 4	  
could address this challenge by delivering an in vitro platform with the capacity to 5	  
characterize which of these loci are expressed in biliary tissue and enable further 6	  
studies on their function and mechanism of action. 7	  
 8	  
Modeling hepatotoxicity and Drug Induced Liver Injury  9	  
Hepatotoxicity constitutes the second most common cause for drug failure in human 10	  
(58), while Drug Induced Liver Injury (DILI) accounts for 50% of acute liver failure 11	  
cases (59). The mechanisms controlling drug sensitivity and idiosyncratic reactions 12	  
remain largely unknown. Genetic factors are considered to play a major role; 13	  
however limited access to primary tissue precludes the development of large scale in 14	  
vitro platforms capturing the genetic diversity of a population and allowing in-depth 15	  
genomic studies. HLCs could overcome this limitation by providing large numbers of 16	  
isogenic cells capable of reproducing the effects of various therapeutic compounds in 17	  
vitro. However, the differences in drug metabolism between primary hepatocytes and 18	  
HLCs remain a significant limitation that needs to be assessed and addressed in 19	  
order to maximize the potential of HLC-based platforms for modeling hepatotoxicity 20	  
and DILI. The development of new protocols (16,20,24) could provide novel 21	  
perspectives towards achieving this goal. Furthermore, the recent development of 22	  
extensive hIPSC libraries such as the HipSci project (http://www.hipsci.org/), 23	  
combined with advances in automated cell culture and high throughput techniques 24	  
(60-61), provide an excellent infrastructure for deriving substantial cohorts of HLCs 25	  
reproducing the genetic variability and polymorphisms accounting of drug toxicity. 26	  
High-throughput sequencing and phenotyping platforms could enable direct 27	  
comparison of the genetic profiles between HLC cohorts derived from healthy 28	  
16	  	  
individuals and patients with DILI or hypersensitivity reactions in order to identify 1	  
novel genetic variants associated with hepatotoxicity. HLCs expressing these 2	  
variants could subsequently be used to interrogate the mechanisms controlling drug 3	  
toxicity and provide more accurate screening platforms for early identification of toxic 4	  
compounds.  5	  
 6	  
Conclusion 7	  
In conclusion, recent technical advances in differentiation protocols combined with 8	  
the development of complex organoid culture systems have significantly improved 9	  
the quality and spectrum of hIPSC-derived liver cell types. As a result hIPSC-based 10	  
liver disease modeling is rapidly expanding from reproducing key phenotypic aspects 11	  
of rare monogenic disorders to modeling diseases representing major causes for 12	  
chronic liver disease and transplantation, such as HCV. In addition, novel 13	  
technologies becoming rapidly available in the field will enable studies at the deepest 14	  
molecular level, linking genetics, epigenetics and phenotype in the context of 15	  
complex liver disorders; thereby pushing the boundaries of regenerative hepatology 16	  
even further in the near future. 17	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Figure Legends 1	  
 2	  
Figure 1 3	  
Strategies the generation of Hepatocyte-Like-Cells (HLCs) from human Induced 4	  
Pluripotent Stem Cells (hIPSCs). Key stages of in vivo liver development are 5	  
compared to in vitro differentiation of HLCs and the growth factors controlling each 6	  
stage are mentioned. Approaches for improving HLC maturation are also 7	  
summarized. 8	  
 9	  
Figure 2 10	  
Liver disease pathways modeled with patient-specific hIPSC-derived 11	  
hepatocytes. The underlying pathophysiology of several hepatic disorders modeled 12	  
in hIPSC-derived hepatocytes is outlined (red) and shown to deviate from the WT 13	  
phenotype (green). (1) α1-Antitrypsin Deficiency: Accumulation of misfolded α1-14	  
antitrypsin in the ER. (2) Familial Transthyretin Amyloidosis: Secretion of 15	  
misfolded protein and formation of extracellular fibrils. (3) Glycogen Storage 16	  
Disease Type 1a: Disruption of enzymatic activity. (4) Familial 17	  
Hypercholesterolemia: Cell membrane receptor dysfunction. (5) Hepatitis C Virus: 18	  
Permissiveness of viral infection and replication. 19	  20	  
25	  	  
Table Legends 1	  
 2	  
Table 1 3	  
Key characteristics of HLCs generated in vitro including expression of liver specific 4	  
markers, in vivo engraftment potential and functionality in comparison to primary 5	  
hepatocytes. 6	  
 7	  
Table 2 8	  
Contribution of hIPSCs to modeling liver disease. Key hepatic disorders leading to 9	  
liver transplantation and relevant hIPSC-based models currently available. 10	  
 
* CYP3A4 activity and albumin secretion in HLCs were compared to those of cryopreserved plated hepatocytes, explaining the level observed. 
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Publication 
Positive 
Control 
Hepatic 
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(RT-PCR, 
ICC, FC, IHC) 
Hepatic Functional Assays Murine 
Engraftment 
in vivo 
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Modeling CYP 3A4 
Metabolic 
Assay  
 
(percentage 
relative to 
primary 
hepatocytes) 
Albumin 
Secretion 
 
(percentage 
relative to 
primary  
hepatocytes) 
Glycogen 
Synthesis /  
Storage 
Cholesterol 
Uptake 
Indocyanine 
Green Uptake 
Du et al. Cell 
Stem Cell 2014 
 
freshly 
isolated human 
primary 
hepatocytes 
ALB  
AAT 
AFP negative 
HNF4A  
CYP3A4  
 
~ 80-270% 
 
~ 60% yes yes yes yes n/a 
Toubul et al. 
Hepatology 
2010, Hannan et 
al. Nature 
Protocols 2013, 
Gieseck et al. 
PLOS ONE 2014 
freshly 
isolated human 
primary 
hepatocytes 
ALB  
AAT  
AFP 
HNF4A 
CYP3A4 
 
~ 10% 
(unpublished) 
~ 75% yes yes yes yes yes 
Ogawa et al. 
Development 
2013 
freshly 
isolated, cryo-
preserved 
human 
primary 
hepatocytes 
ALB  
AAT  
AFP 
HNF4A 
CYP3A4 
~ 900% * ~ 1400% * 
 
n/a n/a yes n/a n/a 
Si-Tayeb et al. 
Hepatology 2010 
cadaveric 
human liver 
samples 
ALB 
AFP 
HNF4A 
CYP3A4 
n/a n/a yes yes yes yes yes 
Hay et al. PNAS 
2008 
primary adult 
human 
hepatocytes 
ALB 
AFP 
HNF4A 
CYP3A4 
n/a n/a yes n/a n/a yes yes 
Etiology 
% of liver 
transplantations hIPSC-based models 
Cirrhosis 
Viral (HBV, 
HCV) 24% 
1. Wu X, et al. (40) 
2. Roelandt P, et al. (41) 
3. Yoshida T, et al. (42) 
4. Schwartz RE, et al. 
(43) 
5. Zhou XL, et al (44) 
Alcohol 19% None available 
Alcohol + virus 3% None available 
Primary Biliary 
Cirrhosis (PBC) 6% None available 
Autoimmune 2% None available 
Secondary 
Biliary Cirrhosis 1% None available 
Cancer 14% None available 
Cholestatic diseases 10% None available 
Acute Hepatic Failure 8% None available 
Metabolic diseases  6% 
Rashid ST, et al. (26) 
Yusa K, et al. (28) 
Rake JP, et al. (31) 
Zhang S, et al. (33) 
Yi F, et al. (34) 
Cayo MA et al. (36) 
Other (Budd Chiari, benign 
liver tumors, polycystic 
disease) 
3% 
Leung A, et al. (30) 
Klotz C et al. (45) 
 


